Cargando…

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis

This study was undertaken to determine the healthcare burden of malignant pleural mesothelioma (MPM) in France and to analyze its associations with socioeconomic deprivation, population density, and management outcomes. A national hospital database was used to extract incident MPM patients in years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chouaid, Christos, Assié, Jean Baptiste, Andujar, Pascal, Blein, Cecile, Tournier, Charlène, Vainchtock, Alexandre, Scherpereel, Arnaud, Monnet, Isabelle, Pairon, Jean Claude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911629/ https://www.ncbi.nlm.nih.gov/pubmed/29479845 http://dx.doi.org/10.1002/cam4.1378

Ejemplares similares

Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
por: Assié, Jean-Baptiste, et al.
Publicado: (2022)

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study
por: Scherpereel, Arnaud, et al.
Publicado: (2018)

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)
por: Chouaïd, Christos, et al.
Publicado: (2017)

Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival
por: Quetel, Lisa, et al.
Publicado: (2020)

Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France
por: Blein, Cecile, et al.
Publicado: (2015)

Hospital burden of pulmonary arterial hypertension in France
por: Bergot, Emmanuel, et al.
Publicado: (2019)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma
por: Meiller, Clément, et al.
Publicado: (2021)

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2022)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
por: Bylicki, Olivier, et al.
Publicado: (2020)

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
por: Alcala, Nicolas, et al.
Publicado: (2019)

Risk factors for early mortality of lung cancer patients in France: A nationwide analysis
por: Goussault, Hélène, et al.
Publicado: (2022)

Predicting survival in malignant pleural mesothelioma using routine clinical and laboratory characteristics
por: Gunatilake, Samal, et al.
Publicado: (2021)

Asbestos Burden Predicts Survival in Pleural Mesothelioma
por: Christensen, Brock C., et al.
Publicado: (2008)

Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma
por: Christensen, Brock C., et al.
Publicado: (2008)

Novel ATP‐competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
por: Yamaji, Masayuki, et al.
Publicado: (2017)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015)

Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis
por: Gendarme, Sébastien, et al.
Publicado: (2021)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis
por: Smeele, Patrick, et al.
Publicado: (2018)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe
por: Moore, Adam, et al.
Publicado: (2022)

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma
por: Sato, Tadashi, et al.
Publicado: (2014)

Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy
por: Desai, Aakash P, et al.
Publicado: (2023)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France
por: Cotté, Francois-Emery, et al.
Publicado: (2016)

Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs
por: Dupuis, Claire, et al.
Publicado: (2021)

Analysis of COVID-19 inpatients in France during first lockdown of 2020 using explainability methods
por: Excoffier, Jean-Baptiste, et al.
Publicado: (2022)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Editorial: Focus on malignant pleural mesothelioma immunology and immunotherapy
por: Porta, Chiara, et al.
Publicado: (2023)

Cost-Effectiveness of an Organized Lung Cancer Screening Program for Asbestos-Exposed Subjects
por: Gendarme, Sébastien, et al.
Publicado: (2022)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
por: Lorenzini, Eugenia, et al.
Publicado: (2022)

Malignant mesothelioma
por: Ruffié, P, et al.
Publicado: (2001)

Increased risk of bone tumors after growth hormone treatment in childhood: A population‐based cohort study in France
por: Poidvin, Amélie, et al.
Publicado: (2018)

Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification
por: Alay, Ania, et al.
Publicado: (2021)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dcfdbrr62hmqmifq3kj4621kbo